Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630563 | 0.83 | KEAP1 (0.62) | KEAP1NFE2L2CNR1CNR2PPARG | |
| SCHEMBL16894157 | 0.77 | KEAP1 (0.71) | KEAP1NFE2L2PPARG | |
| SCHEMBL1630305 | 0.77 | KEAP1 (0.71) | KEAP1NFE2L2CNR1CNR2PPARG | |
| SCHEMBL1630026 | 0.73 | CRHBP (0.49) | CNR1CNR2PSEN1PSEN2APH1B | |
| SCHEMBL1629109 | 0.73 | CRHBP (0.49) | CNR1CNR2PSEN1PSEN2APH1B | |
| SCHEMBL2705416 | 0.72 | CNR1 (0.55) | KEAP1NFE2L2CNR1CNR2LMNA | |
| SCHEMBL1629149 | 0.72 | HCRTR2 (0.58) | KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL1629338 | 0.71 | TRPA1 (0.42) | CNR1CNR2PSEN1PSEN2APH1B | |
| SCHEMBL3422507 | 0.71 | CRHBP (0.51) | CNR1CNR2PSEN1PSEN2APH1B | |
| SCHEMBL1630642 | 0.71 | CRHBP (0.51) | CNR1CNR2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | KEAP1 1802/4885NFE2L2 1690/4885CNR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.